1. Clinical & Scientific Overview
Desvenlafaxine Succinate (TIP-MED-000408, Reference Code [11.18]-C138) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Serotonin–Noradrenaline Reuptake Inhibitors (SNRIs).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [11.18] (Venlafaxine Hydrochloride & Desvenlafaxine Succinate). Representative Indian Market Examples (Edition 2.7 Ch 11 [11.18], p. 148): Venlafaxine ER: Veniz-XR (Sun — 37.5 mg, 75 mg, 150 mg), Venlor-XR (Cipla), Ventab-XL (Intas); Desvenlafaxine ER: D-Veniz (Sun — 50 mg, 100 mg), Desven (Intas), Nexvenla — Strengths & Dosage Forms: Venlafaxine Extended-Release (ER/XR) Capsules/Tablets: 37.5 mg, 75 mg, 150 mg. Desvenlafaxine Extended-Release Tablets: 50 mg, 100 mg.
Venlafaxine Extended-Release (ER/XR) Capsules/Tablets: 37.5 mg, 75 mg, 150 mg. Desvenlafaxine Extended-Release Tablets: 50 mg, 100 mg.
3. Mechanism of Action & Pharmacodynamics
Dual presynaptic inhibition of serotonin (SERT) and noradrenaline (NET) reuptake; Desvenlafaxine (O-desmethylvenlafaxine) is the active metabolite bypassing CYP2D6.
4. Therapeutic Indications & Evidence-Supported Uses
- Major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder, social anxiety disorder, diabetic peripheral neuropathic pain, and vasomotor menopausal symptoms
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Venlafaxine ER: Start 37.5–75 mg PO OD with food; titrate to 75–225 mg OD. Desvenlafaxine ER: 50 mg PO OD (max 100 mg OD).
Administration & Meal Timing: Take Venlafaxine ER WITH food at the same time each morning to reduce nausea; swallow ER capsules/tablets whole (never crush or chew). | Once daily in the morning with breakfast.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [11.18].
Renal: Reduce dose by 25–50% if CrCl <30 mL/min (50 mg alternate days for Desvenlafaxine if CrCl <30). Hepatic: Reduce Venlafaxine dose by 50% in Child-Pugh B/C.
Renal: Reduce dose by 25–50% if CrCl <30 mL/min (50 mg alternate days for Desvenlafaxine if CrCl <30). Hepatic: Reduce Venlafaxine dose by 50% in Child-Pugh B/C.
Renal: Reduce dose by 25–50% if CrCl <30 mL/min (50 mg alternate days for Desvenlafaxine if CrCl <30). Hepatic: Reduce Venlafaxine dose by 50% in Child-Pugh B/C.
7. Contraindications, Precautions & High-Risk Warnings
- DOSE-DEPENDENT HYPERTENSION & SEVERE DISCONTINUATION SYNDROME: Noradrenergic tone increases blood pressure above 150 mg/day (control hypertension before starting). Short half-life (~5h for Venlafaxine) causes severe 'brain zaps', dizziness, and rebound anxiety within 24h of a missed dose.
Key Clinical Precautions: Renal: Reduce dose by 25–50% if CrCl <30 mL/min (50 mg alternate days for Desvenlafaxine if CrCl <30). Hepatic: Reduce Venlafaxine dose by 50% in Child-Pugh B/C.
8. Adverse Effects Profile
- Nausea, dry mouth, diaphoresis (sweating), insomnia or somnolence, constipation, sexual dysfunction, dose-related diastolic BP elevation.
- Serotonin syndrome, sustained hypertension, hyponatraemia (SIADH in elderly), angle-closure glaucoma (mydriasis), suicidality in young adults (<25 yr).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CONTRAINDICATED with MAOIs and Linezolid (14-day washout)
- Additive serotonin syndrome with Tramadol, Tapentadol, Triptans, or Lithium; increased GI bleed risk with NSAIDs/Antiplatelets
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [11.18].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Swallow XR capsules/tablets whole (insoluble ghost shell in stool is normal for matrix tablets); never miss a single day's dose (causes electric-shock sensations/dizziness); check blood pressure regularly.
- Meal & Clock Timing Instruction: Take Venlafaxine ER WITH food at the same time each morning to reduce nausea; swallow ER capsules/tablets whole (never crush or chew). (Once daily in the morning with breakfast.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM (Standard Psychiatric OPD SNRI) | Compendia: NFI 7th Ed 2026 / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Venlafaxine Extended-Release (ER/XR) Capsules/Tablets: 37.5 mg, 75 mg, 150 mg. Desvenlafaxine Extended-Release Tablets: 50 mg, 100 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.1] Sertraline Hydrochloride — Selective Serotonin Reuptake Inhibitor (SSRI Antidepressant & Anx
- [11.2] Escitalopram Oxalate — Selective Serotonin Reuptake Inhibitor (S-Enantiomer of Citalopra
- [11.3] Fluoxetine Hydrochloride — Selective Serotonin Reuptake Inhibitor (Activating Long-Half-Life
- [11.4] Clonazepam — Long-Acting High-Potency Benzodiazepine (GABA-A Receptor Positive
